please make a comparative table 'crysteloids vs colloids' examples indications and compositions from standard medical text books
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. I have enough information to build a detailed, well-cited comparative table. Let me compile this now.
Crystalloids vs Colloids - Comparative Table
Sources: Morgan & Mikhail's Clinical Anesthesiology 7e, Sabiston Textbook of Surgery, Fischer's Mastery of Surgery 8e, Barash Clinical Anesthesia 9e, Mulholland & Greenfield's Surgery 7e
Part 1: Overview Comparison
| Feature | Crystalloids | Colloids |
|---|---|---|
| Definition | Aqueous solutions of ions (salts) with or without glucose | Solutions containing high-molecular-weight substances such as proteins or large glucose polymers, suspended in a crystalloid carrier |
| Mechanism of action | Distribute throughout the entire extracellular fluid (ECF) space; equilibrate rapidly across vascular membranes | Maintain plasma colloid oncotic pressure; remain largely intravascular (limited distribution to plasma volume) |
| Volume of distribution | ~25% stays intravascular (entire ECF); only ~20% of NS remains intravascular | ~70% of infused 5% albumin stays intravascular (Barash 9e) |
| Volume required | 3-4x more volume needed vs colloids to achieve equivalent intravascular expansion | Smaller volumes needed - more "efficient" per mL infused |
| Onset of effect | Moderate | Faster correction of severe intravascular deficits |
| Duration of effect | Short (rapid redistribution) | Longer (hours to days depending on agent) |
| Risk of edema | High with large volumes (>4-5 L); causes tissue, pulmonary, and cerebral edema | Less peripheral/pulmonary edema at equivalent intravascular expansion |
| Effect on oncotic pressure | Decreases plasma oncotic pressure (dilutional) | Maintains or increases plasma oncotic pressure |
| Cost | Inexpensive | Significantly more expensive |
| Coagulopathy risk | Dilutional coagulopathy with large volumes | Dextrans and HES impair platelet adhesiveness and reduce Factor VIII activity; risk of coagulopathy |
| Allergic reactions | Rare | Dextrans: 5% allergic reactions, 0.6% anaphylaxis; HES: 0.006% anaphylaxis (Mulholland 7e) |
| Renal effects | Normal saline: risk of hyperchloremic metabolic acidosis and perioperative AKI | HES: associated with renal impairment and increased need for renal replacement therapy |
| Evidence for mortality benefit | No clear superiority over colloids; crystalloid is standard first-line | No proven mortality benefit over crystalloids; HES may cause harm (Cochrane 2018: 69 RCTs, n=30,020 - Barash 9e) |
Part 2: Crystalloid Solutions - Examples, Compositions, and Indications
(Data from Morgan & Mikhail 7e Table 51-2, Sabiston Table 33.12, Fischer's Table 3.2)
| Solution | Na⁺ (mmol/L) | K⁺ (mmol/L) | Ca²⁺ (mmol/L) | Cl⁻ (mmol/L) | Buffer | Osmolarity (mOsm/L) | pH | Indications |
|---|---|---|---|---|---|---|---|---|
| Human Plasma (reference) | 135-145 | 3.5-5.3 | 2.2-2.6 | 94-111 | HCO₃⁻ 22-26 | 275-295 | 7.35-7.45 | Reference standard |
| 0.9% Normal Saline (NS) | 154 | 0 | 0 | 154 | None | 308 | 4.5-7.0 | Hypochloremic metabolic alkalosis; diluting packed RBCs before transfusion; TBI (mortality benefit over balanced solutions); prehospital resuscitation (convenient single-fluid stocking) |
| Lactated Ringer's (Hartmann's) | 130 | 4 | 3 | 109 | Lactate 28 mmol/L | 273-278 | 5.0-7.5 | Hemorrhagic shock (initial resuscitation); perioperative fluid replacement; burns; septic shock; preferred balanced solution (lower Cl⁻ than NS, less hyperchloremia) |
| Plasma-Lyte A / 148 | 140 | 5 | 0 | 98 | Acetate 27 + Gluconate 23 mmol/L | 295 | 7.4 | Perioperative use; organ transplantation/preservation; patients at risk for hyperchloremia; kidney transplant (better metabolic profile vs NS and LR); platelet storage medium |
| Normosol-R | 140 | 5 | 0 | 98 | Acetate 27 + Gluconate 23 mmol/L | 295 | ~7.4 | Similar to Plasma-Lyte; general perioperative resuscitation; balanced electrolyte replacement |
| 5% Dextrose in Water (D5W) | 0 | 0 | 0 | 0 | None | 252 (effective 0 after glucose metabolism) | ~4.0 | Pure water deficits; maintenance fluid in sodium-restricted patients; hyperosmolar states |
| 3% Hypertonic Saline | ~513 | 0 | 0 | ~513 | None | ~1026 | - | Severe symptomatic hyponatremia; raised ICP/TBI (reduces cerebral edema) |
| D5½NS (D5 in 0.45% NaCl) | 77 | 0 | 0 | 77 | None | ~406 | - | Standard postoperative maintenance fluid in adults (with 20 mEq KCl added) |
"Normal saline, when given in large volumes, produces hyperchloremic metabolic acidosis because of its high chloride content and lack of bicarbonate. In addition, chloride-rich crystalloids such as normal saline may contribute to perioperative acute kidney injury. Therefore, we prefer balanced salt solutions for most perioperative uses." - Morgan & Mikhail's Clinical Anesthesiology 7e
Part 3: Colloid Solutions - Examples, Compositions, and Indications
(Data from Morgan & Mikhail 7e, Mulholland & Greenfield 7e, Barash 9e, Sabiston)
| Solution | Type / Composition | Molecular Weight | Oncotic Effect | Duration | Indications | Key Adverse Effects |
|---|---|---|---|---|---|---|
| 5% Human Albumin | Natural protein; 5 g albumin/100 mL in normal saline carrier; iso-oncotic | 69 kDa | Iso-oncotic; ~70% stays intravascular | 16-24 hours | Hypovolemia when crystalloid insufficient; burns (after 24h); spontaneous bacterial peritonitis; hepatorenal syndrome; septic shock (post hoc ALBIOS: reduced 90-day mortality in septic shock subgroup) | Expensive; may depress immunoglobulin levels; suppresses albumin synthesis; not recommended in TBI (SAFE trial: increased mortality vs NS in TBI patients) |
| 25% Human Albumin | Concentrated albumin; hyper-oncotic | 69 kDa | Hyper-oncotic; draws IFV into plasma | - | Hypoproteinemia; hypoalbuminemia; hepatic failure with ascites; volume-sparing resuscitation | Same as 5% albumin |
| Dextran 40 (10%) | Polysaccharide glucose polymer; hyper-oncotic | 40 kDa | Hyper-oncotic; initial large volume expansion then rapid excretion | Shorter duration (rapidly excreted via kidneys) | Peripheral vascular disease; hyperviscosity syndromes; microcirculation improvement; post-surgery DVT prophylaxis | Decreased platelet adhesiveness; decreased Factor VIII; up to 5% allergic reactions, 0.6% anaphylaxis (Mulholland 7e); renal tubular damage in high doses |
| Dextran 70 (6%) | Polysaccharide glucose polymer; iso-oncotic | 70 kDa | Volume expansion slightly > volume infused; maintained up to 48 hours | Up to 48 hours | General volume expansion; IV fluid resuscitation where prolonged effect needed | Same as Dextran 40 (coagulopathy, anaphylaxis); less renal excretion issues |
| Hydroxyethyl Starch - HES (6% or 10%) | Modified amylopectin (starch) polymer | Variable (130-450 kDa depending on generation) | Good volume expansion for ~36 hours | ~36 hours | Perioperative volume expansion; resuscitation in hemorrhagic shock | Coagulopathy (impairs platelet function, reduces Factor VIII/vWF); pruritus; renal impairment; increased need for renal replacement therapy (Cochrane 2018); anaphylaxis 0.006% - CONTRAINDICATED in sepsis/ICU (Mulholland 7e) |
| Pentastarch (10%) | Lower-MW HES derivative | Lower MW; fewer hydroxyethyl groups | Good volume expansion | ~2.5 hours (shorter than HES) | Short-term volume expansion; fewer side effects than standard HES | Less coagulopathy than standard HES; fewer side effects overall |
| Gelatin (4% - Haemaccel, Gelofusine) | Degraded collagen (bovine); succinylated or urea-linked | ~30-35 kDa | Short duration (rapidly cleared) | 2-4 hours | General volume expansion; perioperative use; trauma resuscitation | Allergic reactions; anaphylaxis; may worsen coagulopathy in large volumes; Cochrane 2018 noted adverse event reports specific to gelatin |
| Fresh Frozen Plasma (FFP) | Plasma with all coagulation factors | Variable | Contributes to oncotic pressure | Duration of clotting factor activity | Coagulopathy with massive transfusion; DIC; reversal of warfarin; massive hemorrhage (1:1 ratio with pRBCs associated with reduced mortality in severe trauma) | Transfusion reactions; TRALI; volume overload; infection risk |
Part 4: Key Clinical Principles (Textbook Summaries)
| Principle | Source |
|---|---|
| Crystalloids, when given in sufficient amounts, are just as effective as colloids in restoring intravascular volume | Morgan & Mikhail 7e |
| Replacing intravascular volume deficit with crystalloids requires 3-4x the volume needed with colloids | Morgan & Mikhail 7e |
| Rapid administration of large crystalloid volumes (>4-5 L) often leads to tissue edema impairing oxygen transport, wound healing, and bowel recovery | Morgan & Mikhail 7e |
| Severe intravascular fluid deficits can be more rapidly corrected using colloid solutions | Morgan & Mikhail 7e |
| Colloid infusion has NOT demonstrated significant benefit over crystalloid resuscitation alone; NOT currently recommended as first-line in hypovolemic shock | Mulholland & Greenfield 7e |
| HES associated with higher mortality and need for renal replacement therapy; HES probably slightly increases need for blood transfusion and RRT | Barash 9e (Cochrane 2018) |
| No available evidence from randomized trials to support colloid use over crystalloid to reduce risk of death | Schwartz's Principles of Surgery 11e |
| Albumin in septic shock: ALBIOS trial showed no difference in 28-day mortality, but 90-day mortality benefit in septic shock subgroup | Barash 9e |
Summary: Crystalloids are the first-line resuscitation fluid in most clinical scenarios due to their lower cost, equivalent efficacy in adequate volumes, and favorable safety profile. Colloids (particularly albumin) may be considered when rapid correction of severe intravascular deficit is needed, when large crystalloid volumes would be harmful, or in specific conditions such as spontaneous bacterial peritonitis or burns after 24 hours. HES is generally avoided in ICU/sepsis settings due to renal harm. The crystalloid vs. colloid debate remains ongoing, but current evidence does not support routine colloid use over crystalloids.
can you make a single concise table for undergrad mbbs students
Here's a clean, single table pitched at MBBS level:
Crystalloids vs Colloids — Quick Reference Table
| Feature | Crystalloids | Colloids |
|---|---|---|
| Definition | Aqueous solutions of salts ± glucose | Solutions containing large molecules (proteins/polymers) in a crystalloid carrier |
| Examples | Normal saline (0.9% NaCl), Lactated Ringer's, Plasma-Lyte, D5W, 3% saline | Albumin (5%, 25%), Dextran 40/70, HES (Hetastarch), Gelatin (Haemaccel) |
| Composition | Small ions (Na⁺, K⁺, Cl⁻, lactate/acetate) | High-molecular-weight substances + crystalloid carrier |
| Distribution | Entire ECF (only ~20% stays intravascular) | Mostly intravascular (~70% of albumin stays in plasma) |
| Volume needed | 3-4x more to achieve same intravascular effect | Smaller volumes needed (more "efficient") |
| Oncotic pressure | Decreases plasma oncotic pressure | Maintains or raises plasma oncotic pressure |
| Duration of effect | Short (rapid redistribution) | Longer (hours to days) |
| Main indications | Hemorrhagic shock (first-line), septic shock, burns, TBI, routine perioperative fluid, dehydration | Rapid correction of severe hypovolemia, hypoalbuminemia, burns (after 24h), SBP, HES contraindicated in sepsis |
| Advantages | Cheap, widely available, safe, replaces ECF deficit too | Rapid volume expansion, less total volume, less edema |
| Disadvantages | Large volumes cause edema, hyperchloremic acidosis (NS), dilutional coagulopathy | Expensive, coagulopathy (dextran/HES), anaphylaxis, HES causes renal injury |
| Cost | Inexpensive | Expensive |
| First-line use? | YES - first-line in most scenarios | No - second-line or specific indications |
Crystalloid Compositions at a Glance
| Solution | Na⁺ | K⁺ | Cl⁻ | Buffer | Osmolarity | Use |
|---|---|---|---|---|---|---|
| 0.9% Normal Saline | 154 | 0 | 154 | None | 308 | Alkalosis, TBI, diluting blood |
| Lactated Ringer's | 130 | 4 | 109 | Lactate 28 | 273 | Shock, burns, surgery |
| Plasma-Lyte | 140 | 5 | 98 | Acetate + Gluconate | 295 | Balanced replacement, transplant |
| D5W | 0 | 0 | 0 | None | 252 | Pure water deficit, Na⁺ restriction |
| 3% Saline | 513 | 0 | 513 | None | 1026 | Severe hyponatremia, raised ICP |
(All values in mmol/L. Source: Morgan & Mikhail's Clinical Anesthesiology 7e, Sabiston Textbook of Surgery)
One-line rule to remember: Give crystalloids first - 3 to 4x the volume. Use colloids when rapid intravascular expansion is needed or large crystalloid volumes would cause harm.
what is HEs in colloids
Finding Sources
Reading File
Here is a complete explanation of HES for MBBS level:
HES = Hydroxyethyl Starch
What is it?
HES is a synthetic colloid made from amylopectin (a plant starch from corn or potatoes) that has been chemically modified by attaching hydroxyethyl (-OCH₂CH₂OH) groups to glucose units. This modification slows the breakdown of starch by serum amylase, making it last longer in the bloodstream.
How it works
- The large starch molecules cannot cross the capillary wall, so they stay inside blood vessels
- They exert oncotic pressure (like albumin), drawing fluid into the intravascular space
- Result: good plasma volume expansion lasting approximately 36 hours
Common preparations
| Preparation | Concentration | Molecular Weight | Generation |
|---|---|---|---|
| Hetastarch (HES 450/0.7) | 6% | 450 kDa | 1st gen |
| Pentastarch (HES 200/0.5) | 10% | 200 kDa | 2nd gen |
| Tetrastarch - Voluven (HES 130/0.4) | 6% | 130 kDa | 3rd gen (lowest side effects) |
The numbers mean: molecular weight / degree of substitution (how many glucose units carry a hydroxyethyl group).
Why HES fell out of favour (important for exams)
| Problem | Detail |
|---|---|
| Nephrotoxicity | Accumulates in renal tubular cells - causes acute kidney injury and increased need for renal replacement therapy (RRT) |
| Coagulopathy | Reduces Factor VIII and vWF activity; impairs platelet function |
| Pruritus | Deposits in skin causing severe, long-lasting itching |
| Mortality | "6S Trial" showed HES associated with increased risk of death and end-stage renal failure vs Ringer's acetate |
| Cochrane 2013 | 42 studies, 11,399 patients - HES significantly increased need for RRT (RR 1.31) and kidney failure (RR 1.59) |
"The Surviving Sepsis Campaign recommended that HES be eliminated from treatment of septic patients." - Barash Clinical Anesthesia 9e
Current status
- Contraindicated in: sepsis, ICU patients, renal impairment, coagulopathy
- Still occasionally used in elective perioperative settings in some countries
- Largely replaced by crystalloids and albumin in modern practice
Simple memory hook: HES = Harms Even with Small doses in sick patients - avoid in sepsis and kidney disease.
why is it colloids are contraindictaed in septic shock?
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
I now have excellent textbook content to give a thorough, well-structured answer. Here it is:
Why Colloids Are Problematic (and largely contraindicated) in Septic Shock
The key lies in understanding what sepsis does to the capillary wall.
Normal physiology - why colloids work
In a healthy person, the capillary wall acts as a semi-permeable barrier. Large colloid molecules (albumin, HES) cannot cross it, so they stay intravascular, exert oncotic pressure, and hold fluid inside the blood vessel. This is the whole point of colloids.
What sepsis does - the core problem
In septic shock, the systemic inflammatory response (cytokines, TNF-α, IL-1, histamine, PAF) causes widespread endothelial damage and increased capillary permeability - sometimes called "capillary leak syndrome."
The capillary wall essentially becomes "leaky" - its pores widen and the glycocalyx (the protective protein lining of capillary endothelium) is destroyed.
Why colloids backfire in this setting
| Step | What happens |
|---|---|
| 1 | Capillary walls become leaky due to sepsis-driven endothelial injury |
| 2 | Colloid molecules (which are normally too big to cross) now escape into the interstitium |
| 3 | Colloid in the interstitium exerts oncotic pressure from outside, actively pulling more fluid out of vessels |
| 4 | Net result: worsening interstitial and pulmonary edema, not plasma expansion |
| 5 | Reduced plasma-interstitial oncotic gradient means the therapeutic advantage of colloids is completely lost |
"Colloids given in the face of pulmonary injury can extravasate, promoting edema because of the reduced plasma-interstitial oncotic gradient." - Mulholland & Greenfield's Surgery 7e
Why HES is specifically contraindicated in sepsis
Beyond the capillary leak problem, HES has additional toxicity in septic patients:
| Mechanism | Consequence |
|---|---|
| HES deposits in renal proximal tubular cells | Osmotic nephrosis - acute tubular injury |
| Impairs glomerular filtration | Acute kidney injury (AKI) |
| Sepsis already compromises renal perfusion | HES dramatically worsens renal outcomes |
| 6S Trial: HES vs Ringer's acetate in sepsis | HES = higher risk of death + end-stage renal failure |
| Cochrane 2013 (42 trials, 11,399 patients) | HES increased need for RRT (RR 1.31) and kidney failure (RR 1.59) |
"The Surviving Sepsis Campaign recommended that HES be eliminated from treatment of septic patients." - Barash Clinical Anesthesia 9e
What about albumin in sepsis?
Albumin is a nuanced exception - it is not absolutely contraindicated (unlike HES), but evidence is mixed:
- ALBIOS trial: No difference in 28-day mortality, but post hoc analysis showed reduced 90-day mortality in septic shock subgroup
- SAFE trial: Albumin was safe but showed no overall mortality benefit
- Albumin also has a rapid flux across leaky pulmonary capillaries and can delay post-resuscitation diuresis
- Current guidance: albumin may be considered after adequate crystalloid resuscitation in sepsis, but is not first-line
Summary - the 3 reasons colloids fail in septic shock
1. CAPILLARY LEAK → colloids escape into interstitium → worsen edema, no plasma expansion
2. HES NEPHROTOXICITY → tubular deposits → AKI in already-compromised kidneys
3. NO PROVEN BENEFIT → crystalloids equally effective when given in adequate volumes
First-line fluid in septic shock = Crystalloids (isotonic, balanced solutions like Lactated Ringer's or Plasma-Lyte), 30 mL/kg bolus as per Surviving Sepsis Campaign guidelines.
examples of dializable drugs/substances
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
I have enough from the textbooks. Now let me compile a comprehensive, well-organized answer.
Dialyzable Drugs and Substances
(Source: Katzung's Basic & Clinical Pharmacology 16e, Goldman-Cecil Medicine, Tintinalli's Emergency Medicine, Tietz Textbook of Laboratory Medicine)
Properties That Make a Drug Dialyzable
A drug is effectively removed by hemodialysis if it has most of the following:
| Property | Dialyzable | NOT Dialyzable |
|---|---|---|
| Molecular weight | Small (<500 Da) | Large (>1000 Da) |
| Protein binding | Low (<80%) | High (>80%) |
| Volume of distribution (Vd) | Small (<1 L/kg) - stays in blood | Large (>2 L/kg) - hides in tissues |
| Water solubility | High (hydrophilic) | Low (lipophilic) |
| Endogenous clearance | Low (body can't clear it fast) | High (liver/kidney already clearing it) |
"The efficiency of hemodialysis is a function of the molecular weight, water solubility, protein binding, endogenous clearance, and distribution in the body of the specific toxin." - Katzung's Pharmacology 16e
Dialyzable Substances - Organized by Category
Toxins & Overdoses (Most Important Clinically)
| Substance | Why Dialysis Helps | Notes |
|---|---|---|
| Salicylates (Aspirin) | Small MW, low protein binding in overdose, water-soluble | Best indication; also correct acid-base; level >90-100 mg/dL = emergency HD |
| Methanol (wood alcohol) | Removes parent compound + toxic metabolite formic acid | Formic acid causes blindness/metabolic acidosis; combine with fomepizole |
| Ethylene glycol (antifreeze) | Removes parent compound + oxalic acid & glycolic acid | Oxalate causes renal failure; HD if level >50 mg/dL |
| Lithium | Very small ion (MW 7), not protein-bound, low Vd | Classic dialyzable drug; levels >4 mEq/L or severe toxicity = HD |
| Isopropyl alcohol | Small, water-soluble | Also removes toxic metabolite acetone |
| Theophylline | Small MW, moderate protein binding | Chronic toxicity less responsive than acute; HD for severe cases |
| Phenobarbital | Small MW, moderate protein binding | Long-acting barbiturate; HD clears it effectively |
| Metformin | Small MW, not protein bound, water soluble | HD especially in metformin-associated lactic acidosis (MALA) |
| Bromide | Small ion | Historic use; bromide toxicity (bromism) |
Antibiotics (Dose adjustment needed in renal failure; partially/fully removed by HD)
| Drug | Dialyzable? | Notes |
|---|---|---|
| Aminoglycosides (gentamicin, amikacin) | YES | Low protein binding; supplemental dose after HD |
| Vancomycin | Partially (with high-flux dialysis) | Low-flux dialysis removes very little; high-flux removes ~30% |
| Metronidazole | YES | Low protein binding |
| Cephalosporins (cefazolin, ceftriaxone) | Most YES | Supplement dose after HD |
| Penicillins (ampicillin, amoxicillin) | YES | Low protein binding |
| Carbapenems (imipenem, meropenem) | YES | Dose supplement needed post-HD |
| Acyclovir | YES | Low protein binding; dose after HD |
| Ganciclovir | YES | Supplement post-HD |
| Trimethoprim | Partially | |
| Fluconazole | YES | Low protein binding (~11%) |
Cardiovascular Drugs
| Drug | Dialyzable? | Notes |
|---|---|---|
| Atenolol | YES | Hydrophilic beta-blocker; supplement after HD |
| Sotalol | YES | Hydrophilic; not protein bound |
| Procainamide | YES | Supplement after HD |
| Captopril | YES | Low protein binding |
| Enalaprilat | YES | |
| Lisinopril | YES |
CNS Drugs
| Drug | Dialyzable? | Notes |
|---|---|---|
| Lithium | YES (very well) | Prototype dialyzable drug - small ion, no protein binding |
| Phenobarbital | YES | Supplement after HD |
| Gabapentin | YES | Not protein bound; major dose reduction in renal failure |
| Pregabalin | YES | Similar to gabapentin |
| Topiramate | Partially |
Miscellaneous
| Drug | Dialyzable? |
|---|---|
| Alcohol (ethanol) | YES - but HD rarely needed as liver clears it fast |
| Paracetamol (acetaminophen) | Partially - but NAC is antidote; HD rarely indicated |
| Urea, creatinine, uric acid | YES - the whole point of dialysis in renal failure |
| Potassium, phosphate | YES - corrected with each HD session |
| Methotrexate | YES (with high-flux) - in toxicity |
NOT Dialyzable (Drugs to Know)
| Drug | Why NOT Dialyzable |
|---|---|
| Digoxin | Very high Vd (7 L/kg) - hides in tissues |
| Tricyclic antidepressants (amitriptyline) | High protein binding + high Vd + lipophilic |
| Phenytoin | >90% protein bound |
| Benzodiazepines (diazepam) | High lipophilicity, high protein binding |
| Propranolol | Lipophilic, high protein binding |
| Warfarin | >99% protein bound |
| Chloroquine | Enormous Vd (hundreds of L/kg) |
| Antipsychotics (haloperidol, chlorpromazine) | High protein binding + lipophilic |
| SSRIs (fluoxetine) | Very high Vd, lipophilic |
Memory Aid: "SLIME" = Properties of Dialyzable Drugs
S - Small molecular weight (<500 Da)
L - Low protein binding (<80%)
I - Intravascular (low Vd <1 L/kg)
M - Miscible in water (hydrophilic)
E - Endogenous clearance is low
The opposite of SLIME = not dialyzable (large, highly protein-bound, high Vd, lipophilic).
plasma protein binding affinity or percentage bound?
Finding Sources
Finding Sources
Reading File
Finding Sources
Excellent textbook data. Here is the full explanation:
Plasma Protein Binding: Affinity vs. Percentage Bound
These are two different but related concepts. Understanding both is important in pharmacology.
1. Binding Affinity (Ka)
This is the strength of attraction between a drug molecule and its protein binding site - expressed as an association constant (Ka, units: L/mol).
- High Ka = drug "sticks tightly" to the protein
- It describes the quality of the interaction at the molecular level
- Determined by the drug's chemical structure and the protein's binding site geometry
- Can be altered by uremia (conformational change in albumin), competing drugs, or fatty acids
"Binding affinity is influenced by changes in the structural orientation of the albumin molecule or by the accumulation of endogenous inhibitors of protein binding that compete with drugs for their binding sites." - Brenner & Rector's The Kidney
2. Percentage Bound (% Protein Binding)
This is the proportion of total drug in plasma that is attached to protein at any given time - expressed as a percentage.
- e.g., Warfarin = 99% bound → only 1% is FREE
- This is what pharmacology textbooks report for every drug
- Depends on: affinity (Ka) + number of binding sites + drug concentration + competing substances
- It describes how much drug is "captured" vs. "free"
The Key Relationship
% Bound = f(Ka, protein concentration, binding sites, competing ligands)
High affinity usually leads to high % bound - but not always:
- A drug may have high affinity but low % bound if it has few binding sites or is given in high dose (saturation)
- A drug may have low affinity but high % bound if there are many available binding sites (albumin has ~2 binding sites per molecule but is present at 35-50 g/L in plasma)
Why % Bound Matters More for Dialyzability
Dialysis works by filtering the FREE (unbound) drug across a semi-permeable membrane. Only unbound drug is small enough and "available" to be filtered.
| Scenario | Effect on Dialysis |
|---|---|
| Drug 99% bound (e.g., warfarin, phenytoin) | Only 1% free - almost nothing crosses the dialysis membrane → NOT dialyzable |
| Drug 0% bound (e.g., lithium) | 100% free - all drug available to be filtered → Highly dialyzable |
| Drug 50% bound | Half is available - moderate dialyzability |
The Affinity Trap (Clinical Pearl)
Here is where affinity becomes practically important:
In overdose or renal failure, high-affinity binding can be overwhelmed (saturated):
- Normal dose of phenytoin: 90% bound, 10% free
- Overdose or uremia: binding sites saturate → % free rises sharply → toxicity even at "normal" total levels
"The unbound fraction of several acidic drugs is increased in CKD because of impaired plasma protein binding. Toxicity can occur if the total plasma concentration of these drugs is pushed into the therapeutic range by increasing the dose, wherein the free (active) concentration may be in the supratherapeutic range. For such drugs, unbound plasma concentrations should be measured." - Brenner & Rector's The Kidney
Classic example - phenytoin in uremia:
| State | Total phenytoin | Free phenytoin | Clinical effect |
|---|---|---|---|
| Normal | 15 mg/L (therapeutic) | ~1.5 mg/L (10% free) | Therapeutic |
| Uremia | 8 mg/L (looks "low") | ~2.5 mg/L (30% free - uremic toxins displace drug from albumin) | Toxic! |
This is why in renal failure you measure free phenytoin levels, not total.
Summary Table
| Feature | Binding Affinity (Ka) | Percentage Bound |
|---|---|---|
| What it measures | Strength of drug-protein interaction | Proportion of drug attached to protein |
| Units | L/mol (or M⁻¹) | % |
| What it tells you | How tightly drug binds | How much drug is "captured" vs free |
| Dialyzability | Indirect relationship | Direct determinant - only free drug is dialyzable |
| Clinical use | Explains drug displacement interactions | Guides dosing, dialysis decisions, toxicity monitoring |
| Changes in disease | Altered by uremia, hypoalbuminemia, pH | Falls in uremia/hypoalbuminemia → more free drug → toxicity |
Bottom line: For dialyzability - use % protein bound. A drug >80% bound is generally not well dialyzable regardless of affinity, because too little free drug exists in plasma to be filtered. Affinity matters more when you are thinking about drug-drug displacement interactions (e.g., sulfonamides displacing warfarin from albumin).
This is a shared conversation. Sign in to Orris to start your own chat.